A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies

NCT04543305 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma
Acute Myeloid Leukemia
Non Hodgkin Lymphoma
Myelodysplastic Syndromes

Interventions

DRUG: PRT1419

Sponsor

Prelude Therapeutics